Wayne Koberstein

  1. Companies To Watch: Osivax 10/1/2020

    Osivax is developing universal vaccines for influenza, coronaviruses, and other infectious diseases such as malaria and human papillomavirus (HPV). Preclinical studies also have started on a coronavirus vaccine, which would include Covid-19.

  2. Eyes On Horizon, Buying Into Bio 9/1/2020

    CEO Tim Walbert talks about how his company, Horizon Therapeutics, has gone from acquiring commercial drugs and remarketing them to using their R&D to focus more on bio-based medicines such as monoclonal antibodies and genetically engineered proteins.

  3. Companies To Watch: CalciMedica 9/1/2020

    “In a sense, the Covid association was a golden opportunity for our drug,” says Rachel Leheny, CEO of CalciMedica, a pharma focused on anti-inflammatories for pancreatitis that has now shifted to treatments for Covid-19 pneumonia.

  4. The Co-Opportunities Of COVID-19 8/3/2020

    An interview with Arda Ural, Ph.D., who leads the life sciences team at Ernst & Young, which is tracking biopharma’s readiness and reaction to the COVID-19 pandemic.

  5. Companies To Watch: Cidara Therapeutics 8/3/2020

    Cidara Therapeutics is training its novel treatment and preventative for flu and other viral infections on Covid-19.

  6. The Viral Startup 7/1/2020

    ViralClear, formed in March 2020 to obtain a drug whose potential use against COVID-19 already has substantial support in evidence. The company is employing considerable industry expertise to move it into clinical development.

  7. Companies To Watch: Equillium 7/1/2020

    Equillium is keeping a close eye on the COVID-19 challenge, but sticking to acute GVHD, uncontrolled asthma, and lupus nephritis as primary inflammation targets.

  8. Companies To Watch: Spring Bank Pharmaceuticals 6/1/2020

    Spring Bank Pharmaceuticals is continuing clinical programs during the COVID-19 challenge and advancing novel approaches to cancer, inflammation, and viruses.

  9. Companies To Watch: argenx 5/1/2020

    Argenx is developing new antibody therapeutics for immunological diseases in the neuromuscular, hematology, oncology, and other areas. The company has a full pipeline of candidates and indications.

  10. A European Model For Innovative Bio Funding 5/1/2020

    Challenge breeds creativity, and a fresh example of that has emerged in Germany’s Ruhr Valley, with the company Abalos Therapeutics and the unique funding model that supported its launch.